北京若生智能科技有限公司
Drug Database
AT

atenolol (Anselol / atenolol, Douglas)

✓ Approved

Douglas Pharmaceuticals Limited · ADRB1 · 小分子

什么是 atenolol？

atenolol 是一种小分子，由Douglas Pharmaceuticals Limited研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Anselol, atenolol, Douglas
公司Douglas Pharmaceuticals Limited
药物类别小分子
分子靶点ADRB1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Douglas Pharmaceuticals Limited

作用机制

分子靶点

atenolol 作用于 1 个分子靶点：

ADRB1adrenoceptor beta 1 (B1AR, RHR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

atenolol 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAngina pectoris✓ Approved
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedCureus2026-10-23

Newly Diagnosed Graves' Disease Followed by the Discovery of a Cavernous Internal Carotid Artery Aneurysm Causing Panhypopituitarism: A Case Report.

Touffaha Ibrahim M IM, Elhomsy Georges G

Sellar and parasellar vascular lesions are rare causes of pituitary dysfunction and may mimic pituitary adenomas or other sellar masses. Cavernous internal carotid artery (ICA) aneurysms can cause hypopituitarism through compression of the pituitary gland or stalk, but diagnosis may be delayed when symptoms are initially attributed to a more common endocrine disorder. We report a 37-year-old man who presented with six weeks of unintentional weight loss, fatigue, heat intolerance, excessive sweating, anxiety, tremor, and tachycardia. Initial evaluation showed suppressed thyroid-stimulating hormone (TSH), elevated total triiodothyronine (T3), positive thyrotropin receptor antibody, positive thyroid-stimulating immunoglobulin, and a hypervascular thyroid gland on ultrasound, consistent with Graves' disease. He was started on methimazole and atenolol. Although thyroid function tests improved, he developed persistent neck discomfort, prompting contrast-enhanced computed tomography (CT), which revealed an enhancing sellar mass. Magnetic resonance imaging (MRI) showed a T2-hypointense sellar lesion with internal flow artifact, and CT angiography confirmed a saccular aneurysm of the cavernous segment of the right ICA. Pituitary hormone evaluation demonstrated secondary adrenal insufficiency, central hypothyroidism, hypogonadotropic hypogonadism, growth hormone (GH) deficiency, and mild hyperprolactinemia, consistent with panhypopituitarism from pituitary compression. The patient was started on prednisone and levothyroxine, and atenolol and prednisone were subsequently discontinued before endovascular embolization was performed. At follow-up, symptoms improved, but panhypopituitarism persisted. This case highlights the importance of reassessing patients when endocrine symptoms evolve despite an initially appropriate diagnosis.

PMID 42910339
阅读全文 →
PubMedBriefings in bioinformatics2026-10-19

Metabolomics workbench: data-driven classification and correlation analysis between metabolite classes, biomarkers, and drugs.

Khandokhin Mikhail M MM, Sokolov Aleksandr A, Oskolkov Nikolay N, Fredriksson Robert R et al.

Public repositories now accumulate an unprecedented amount of metabolomics data. Despite the opportunities for large-scale meta-analyses opened by these repositories, the deposited data rarely becomes systematically re-analyzed. We conducted a systematic metadata-based re-analysis of all human blood metabolomics studies in the Metabolomics Workbench performed using Orbitrap or QTOF mass spectrometry, encompassing 44 165 samples. After harmonizing metabolites with PubChem identifiers and embedding them using SMILES representations, we generated a map of 6752 blood metabolites forming 25 structural clusters, and subsequently performed correlation analysis between these clusters, biomarkers, and drugs. Analysis of 337 120 metabolite pairs detected in at least 10 studies showed that structurally related clusters display correlated abundances (ρ up to 0.6). Correlation patterns among established clinical biomarkers revealed candidate metabolic correlates, several with ρ > 0.7. We also developed open-source software enabling similar analyses for any metabolite across the Workbench data explored. Additionally, curating drug-containing datasets enabled meta-analyses for compounds such as acetaminophen, metoprolol, and atenolol, identifying both known and novel metabolic signatures. Besides the biological insights, we have found that Orbitrap and QTOF tend to detect different metabolites, but they give quantitatively coherent results on overlapping compounds. Overall, the present study provides the methodology and software to perform large-scale mining of public metabolomics data enabling its re-analysis to obtain novel biomedical insights.

PMID 42894388
阅读全文 →
PubMedCase reports in urology2026-10-13

Catecholamine-Secreting Retroperitoneal Paraganglioma: A Case Report and Literature Review.

Felício Eduardo E, Gião Nuno N, Bernardo Guilherme G, Barcelos André A et al.

Paragangliomas are rare neuroendocrine tumors arising from autonomic paraganglia. These tumors have metastatic potential, and histopathological findings alone cannot reliably predict their biological behavior. Clinical manifestations range from the classic triad of headache, diaphoresis, and palpitations to incidental findings in asymptomatic patients. A 75-year-old man was incidentally found to have a 5 cm retroperitoneal mass adjacent to the right renal hilum. Biochemical testing confirmed marked catecholamine hypersecretion, and 18F-FDOPA PET/CT demonstrated isolated uptake within the lesion without additional disease. Preoperative preparation included progressive alpha-adrenergic blockade with doxazosin for approximately 1 month, followed by atenolol for heart rate control. An open approach through a right subcostal hemichevron incision was selected because the tumor was located between the right renal artery and vein and lateral to the inferior vena cava. During dissection, an iatrogenic renal artery injury with intraoperative hemorrhage occurred, necessitating en bloc removal of the tumor, right kidney, and right adrenal gland. Histopathological examination confirmed a paraganglioma with a Ki-67 proliferation index below 1%, focal nuclear atypia, no mitotic figures, no tumor necrosis, no vascular invasion, and microscopic margin involvement. Immunohistochemistry was positive for Chromogranin A, synaptophysin, GATA-3, and S100. Germline testing using a 14-gene pheochromocytoma-paraganglioma panel identified no reported pathogenic or likely pathogenic variants. At 6 months, contrast-enhanced thoracoabdominopelvic computed tomography showed no evidence of local recurrence or metastatic disease, and plasma and urinary metanephrines had normalized, consistent with postoperative biochemical remission. The patient remains under joint endocrinology and urology follow-up with lifelong annual clinical and biochemical surveillance. This case highlights the diagnostic and surgical challenges of a functioning perihilar retroperitoneal paraganglioma. Careful endocrine preparation, vascular planning, multidisciplinary management, and lifelong surveillance are essential, particularly when the surgical margin is microscopically involved.

PMID 42865698
阅读全文 →
PubMedSchweizer Archiv fur Tierheilkunde2026-10-06

Percutaneous balloon valvuloplasty in a small cat with pulmonary valve stenosis and concomitant tricuspid valve dysplasia.

Hipp H M HM, Schreiber N N, Wieser M L ML, Pereira N N et al.

A 14-month-old, male castrated, 3,9-kg Singapura cat was referred for treatment of severe pulmonary valve stenosis associated with tricuspid valve dysplasia. The cat was pretreated with atenolol and scheduled for pulmonary balloon valvuloplasty. Because the right femoral vein could not accommodate a 5 Fr introducer, vascular access was obtained via the left external jugular vein, followed by right ventricular catheterisation, pressure measurement and angiography. A 10 mm low pressure balloon catheter was advanced over a guidewire to the level of the pulmonary valve and inflated once, resulting in complete loss of the balloon waist. During the procedure, the cat was severely hypotensive for 30 minutes, lasting from the time of ca-theterisation of the right ventricular outflow tract until nearly the end of anaesthesia. Postoperative tachypnoea was attributed to congestive heart failure, although aspiration pneumonia could not be excluded. The patient was discharged the day after the intervention following a single dose of furosemide and received amoxicillin-clavulanate for ten days. Echocardiography after eleven days, three months and 16 months demonstrated a marked and sustained reduction of the transvalvular pressure gradient. The cat showed an improved activity level after the procedure, which persisted over the 16-month follow-up period.

PMID 42834632
阅读全文 →
PubMedEnvironmental science and pollution research international2026-10-06

Efficient enzyme-mediated degradation of various emerging pollutants, including 2-mercaptobenzothiazole, paracetamol, and sulfamethoxazole, using HRP@UiO-66-NH2.

Al-Maqdi Khadega A KA, Alneyadi Shaikha S, Elmerhi Nada N, Siddig Lamia A LA et al.

The increasing contamination of water sources due to industrialization and population growth poses significant environmental and health risks, even at trace pollutant concentrations. Enzymatic bioremediation, particularly using horseradish peroxidase (HRP), has shown great potential in pollutant degradation due to its high selectivity and catalytic efficiency. However, limitations such as poor operational stability and reusability hinder its large-scale application. The degradation of structurally diverse emerging pollutants by UiO-66-NH2-immobilized HRP, including the influence of redox mediation, remains insufficiently investigated. This study addresses this gap by immobilizing HRP onto UiO-66-NH2, a metal-organic framework (MOF) with high stability and surface area. HRP@UiO-66-NH2 was characterized using SEM-EDX, PXRD, FTIR, TGA, and BET analyses, while pollutant degradation was quantified by LC-MS/MS. HRP loading concentrations ranging from 0.5 to 4 mg/mL were evaluated, and 1 mg/mL was selected for subsequent experiments. The immobilized HRP exhibited an optimum H2O2 concentration of 1.08 mM within the tested range of 0-2.43 mM. Both free and immobilized HRP showed maximum activity at pH 4, while the optimum temperature shifted from 30°C for free HRP to 40°C following immobilization. The immobilized enzyme also retained approximately 95% of its initial activity after four reuse cycles. HRP@UiO-66-NH2 was evaluated for the degradation of nine emerging pollutants, including 2-mercaptobenzothiazole, paracetamol, sulfamethoxazole, methylparaben, salicylic acid, lincomycin hydrochloride, atenolol, thiabendazole, and DEET. It degraded 99.7% of 2-mercaptobenzothiazole and 97.4% of paracetamol within 30 min. The addition of 1-hydroxybenzotriazole (HOBT) increased the degradation of sulfamethoxazole, methylparaben, and salicylic acid from 23.3%, 14.5%, and 12.4% to 53.1%, 57.6%, and 54.3%, respectively. The greater thermal and H2O2 tolerance of immobilized HRP suggests a protective effect of the UiO-66-NH2 framework, while the variable response to HOBT indicates pollutant-dependent redox mediation. These findings highlight HRP@UiO-66-NH2 as a promising biocatalyst for sustainable water remediation, warranting further studies to elucidate the underlying degradation mechanisms and optimize real-world applications.

PMID 42834305
阅读全文 →
PubMedMedicine2026-09-26

Comparative real-world safety profiles of selective β1-adrenergic receptor blockers: A multi-database pharmacovigilance disproportionality study.

Ren Weijie W, Zhao Haosen H, Wang Zhenzhong Z, Li Jixin J et al.

Selective β1-blockers are fundamental in managing hypertension, coronary artery disease, and heart failure. Yet, despite their widespread use, practical guidance on safe and individualized prescribing remains limited. Existing evidence is largely derived from controlled clinical trials, which may not fully capture drug-specific adverse events, sex-related susceptibility, or early-onset risks observed in routine clinical practice. To generate real-world, evidence-based recommendations for the safe use of selective β1-blockers, we compared the adverse event profiles of metoprolol, bisoprolol, and atenolol using 2 large pharmacovigilance systems. Adverse drug events reported for the 3 agents between 2004 and Q2 2025 were retrieved from the US Food and Drug Administration Adverse Event Reporting System, a spontaneous-reporting system, and compared with reports from the Canadian Vigilance Adverse Reaction Online Database. Disproportionality analyses, preferred term mapping, exploratory sex-stratified comparisons, and time-to-onset modeling were conducted to characterize shared reporting patterns, drug-specific signals, and potential patient-level modifiers. Across all 3 agents, disproportionate reporting was observed for a common cardiovascular spectrum that included bradycardia, conduction abnormalities, heart failure, and blood pressure instability. Metoprolol showed prominent reporting signals for BRASH syndrome and neuropsychiatric and suicide-related events. Bisoprolol showed signals for bradyarrhythmia, hyperkalemia, and acute kidney injury. Atenolol showed reporting patterns involving blood pressure perturbations, electrolyte imbalance, and interaction-related events. Exploratory sex-stratified analyses identified differences in the reporting distributions of several PT = preferred terms for metoprolol and atenolol, whereas bisoprolol showed a more balanced distribution. All 3 agents displayed early-failure time-to-onset patterns, supporting closer monitoring after treatment initiation. This real-world pharmacovigilance assessment identifies drug-specific patterns of disproportionate reporting that may inform hypothesis generation and individualized monitoring. Because spontaneous-reporting data cannot establish incidence or causality, the findings should complement, rather than replace, clinical judgment and confirmation in controlled or longitudinal data sources.

PMID 42798089
阅读全文 →

注册免费账户还可查看另外 7889 篇文献

免费注册查看全部文献 →

了解更多atenolol